Calculator inputs
Enter patient and indication details below. Results appear above this form after submission.
Formula used
Mosteller BSA
BSA (m²) = √[(height in cm × weight in kg) / 3600]
DuBois BSA
BSA (m²) = 0.007184 × height(cm)0.725 × weight(kg)0.425
Cockcroft-Gault CrCl
CrCl = ((140 − age) × weight in kg) / (72 × serum creatinine)
Multiply by 0.85 for females.
Pediatric reference logic
Daily dose = 340 mg/m²/day × BSA, capped at 600 mg/day where label applies.
Adjustment logic
Severe hepatic impairment applies a 25% reduction. Moderate renal impairment applies a 50% starting-dose reduction. Hepatotoxicity and cytopenia thresholds trigger hold or reduction rules shown in the result panel.
How to use this calculator
- Choose the disease indication that matches the treatment setting.
- Enter age, sex, weight, height, and serum creatinine when available.
- Pick hepatic status and allow renal category to auto-calculate or override it manually.
- Enter bilirubin, transaminase, ANC, and platelets if you want toxicity rule checks.
- Check the escalation box only when the labeled optional pathway is clinically relevant.
- Submit the form and review the summary, warnings, chart, and interpretation notes.
- Use CSV or PDF export to save the calculation snapshot for documentation.
- Confirm all orders against current labeling, local protocols, and specialist review.
Example data table
| Scenario | Input Summary | Reference Output | Notes |
|---|---|---|---|
| Adult CML CP | Age 48, male, normal organ function | 400 mg/day | Standard chronic phase adult reference dose. |
| Pediatric Ph+ ALL | Weight 28 kg, height 128 cm, BSA by Mosteller | 340 mg/m²/day, capped at 600 mg/day | Use with combination chemotherapy protocols. |
| Adult GIST | Metastatic disease with progression flag selected | Up to 800 mg/day | Usually administered as 400 mg twice daily. |
| Adult moderate renal impairment | CrCl 32 mL/min, base dose 400 mg/day | 200 mg/day starting reference | Future titration depends on tolerability. |
| Liver toxicity hold | Bilirubin 3.4× IULN | Hold therapy | Resume only after laboratory recovery. |
Important clinical notes
- This page is an educational dose-reference aid, not a prescribing substitute.
- Diagnosis confirmation, mutation testing, chemotherapy protocol context, and interaction screening remain essential.
- Pediatric dosing depends on a valid BSA and often protocol-specific oncology oversight.
- Severe renal impairment and complex toxicity scenarios need individualized specialist review.
- Recheck product labeling and institutional guidelines before every treatment decision.
FAQs
1. Does this calculator prescribe imatinib?
No. It only organizes label-based reference logic and toxicity checkpoints. Final prescribing requires clinician judgment, protocol review, pharmacy verification, and current product labeling.
2. Why does the pediatric result need height and weight?
Pediatric CML and pediatric Ph+ ALL use body surface area dosing. Height and weight are needed to calculate BSA and estimate the capped daily reference amount.
3. What renal formula is used here?
The calculator uses Cockcroft-Gault creatinine clearance for adult screening when you choose automatic renal assessment. You can also override renal status manually when clinical data support a different category.
4. Why can the result show a hold instead of a dose?
If bilirubin exceeds 3× IULN or transaminases exceed 5× IULN, the labeled hepatotoxicity rule calls for holding therapy until lab recovery before resuming at a reduced dose.
5. What does the escalation checkbox do?
It applies optional labeled higher-dose pathways for selected indications such as chronic phase CML, advanced CML, certain fusion-associated diseases, or progressing GIST when appropriate.
6. Why is severe renal impairment handled cautiously?
The label does not present a firm routine starting dose for severe renal impairment. It notes limited tolerance data, so individualized specialist review is safer than a hard automatic recommendation.
7. Does the graph replace the table?
No. The graph is a visual summary of the main dose stages. The detailed result table and notes carry the more important interpretation, warnings, and toxicity logic.
8. Can I use this tool for patient self-care?
No. Imatinib treatment requires specialist supervision, indication-specific context, and laboratory monitoring. This page is designed for educational review and documentation support only.